Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 11/20 | 0.58 |
| ▸ | NNMT | P40261 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409319 | 0.80 | PTK2 (0.54) | HCAR3NNMTHDAC1HDAC6MAPT | |
| SCHEMBL14973431 | 0.77 | HCAR3 (0.47) | HCAR3NNMTHDAC1HDAC6MAPT | |
| SCHEMBL641282 | 0.77 | HDAC1 (0.61) | HDAC1HDAC6MAPT | |
| SCHEMBL1728775 | 0.76 | HCAR3 (0.45) | HCAR3HCAR2TDO2 | |
| SCHEMBL1729121 | 0.76 | HCAR3 (0.51) | HCAR3HDAC1HCAR2 | |
| SCHEMBL14061762 | 0.75 | HDAC1 (0.36) | HDAC1HDAC6 | |
| SCHEMBL1725915 | 0.75 | HDAC1 (0.36) | HDAC1HDAC6 | |
| SCHEMBL29854816 | 0.74 | GCK (0.40) | HCAR3NNMTHDAC1HDAC6MAPT | |
| SCHEMBL1483582 | 0.74 | HDAC1 (0.49) | HCAR3NNMTHDAC1HCAR2 | |
| SCHEMBL28810935 | 0.74 | GCK (0.40) | HCAR3NNMTHDAC1HDAC6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018072697-A1 | OXADIAZOLE RING-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, COMPOSITE, AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2018-04-26 | — | — | WO | disclosed |
| US-8791142-B2 | Oxazole pyridine derivatives useful as S1P1 receptor agonists | MERCK SERONO S.A. (CH) | 2014-07-29 | — | — | US | disclosed |
| EP-2403849-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | Merck Serono S.A. (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO SA (CH) | 2011-12-15 | — | — | US | disclosed |
| WO-2010100142-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR5 | HCAR3 173/4885NNMT 3153/4885HDAC1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.